



We Claim:

1. A compound of formula **1**



5 wherein:

A is a group selected from



X^- is an anion with a single negative charge;

R^1 and R^2 are each independently a C_1 - C_4 -alkyl optionally substituted with hydroxy or halogen; and

R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are each independently hydrogen, C_1 - C_4 -alkyl, C_1 - C_4 -alkyloxy, hydroxy, CF_3 , CN, NO_2 , or halogen,

with the proviso that at least one of the groups R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 is not hydrogen.

2. The compounds of formula **1** according to claim 1, wherein:

X^- is an anion selected from the group consisting of chloride, bromide, methylsulfate, 4-toluenesulfonate, and methanesulfonate;

R^1 and R^2 are each independently a group selected from the group consisting of methyl, ethyl, *n*-propyl, and isopropyl, each optionally substituted by hydroxy or fluorine; and

R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF_3 , or NO_2 .

3. The compound of formula **1** according to claim 1, wherein:

X^- is bromide;

R^1 and R^2 are each independently methyl or ethyl; and


R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are each independently hydrogen, methyl, methyloxy, fluorine,
5 chlorine, or bromine.

4. The compound of formula **1** according to claim 3, wherein:

R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are each independently hydrogen, fluorine, chlorine, or bromine.

10 5. The compound of formula **1** according to claim 4, wherein:

A is a group selected from



6. The compound of formula **1** according to claim 5, wherein:

15 R^1 and R^2 are each methyl; and

R^3 , R^4 , R^5 , R^6 , R^7 , and R^8 are each independently hydrogen or fluorine.

7. A pharmaceutical composition comprising a compound of formula **1** according to claim 1
and a pharmaceutically acceptable excipient and/or carrier.

20 8. A pharmaceutical composition comprising a compound of formula **1** according to claim 2
and a pharmaceutically acceptable excipient and/or carrier.

9. A pharmaceutical composition comprising a compound of formula **1** according to claim 3
25 and a pharmaceutically acceptable excipient and/or carrier.

10. A pharmaceutical composition comprising a compound of formula **1** according to claim 4
and a pharmaceutically acceptable excipient and/or carrier.

11. A pharmaceutical composition comprising a compound of formula 1 according to claim 5 and a pharmaceutically acceptable excipient and/or carrier.

12. A pharmaceutical composition comprising a compound of formula 1 according to claim 6 and a pharmaceutically acceptable excipient and/or carrier.

13. The pharmaceutical composition according to claim 7, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

14. The pharmaceutical composition according to claim 8, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

15. The pharmaceutical composition according to claim 9, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

16. The pharmaceutical composition according to claim 10, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

17. The pharmaceutical composition according to claim 11, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

18. The pharmaceutical composition according to claim 12, further comprising an additional active substance selected from the group consisting of betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists, and steroids.

19. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 1.

20. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 2.

21. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 3.

22. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 4.

23. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 5.

24. A method of treating diseases in which anticholinergics may provide a therapeutic benefit, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 6.

25. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 1.

26. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual

disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 2.


27. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 3.

28. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 4.

29. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 5.


30. A method of treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract, or menstrual disorders, comprising administering to a host in need of such treatment a compound of formula **1** according to claim 6.

31. A compound of formula **4**



wherein:

A is a group selected from



R¹ is a C₁-C₄-alkyl optionally substituted with hydroxy or halogen; and

- 5 R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, C₁-C₄-alkyl, C₁-C₄-alkyloxy, hydroxy, CF₃, CN, NO₂, or halogen,

with the proviso that at least one of the groups R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is not hydrogen.

- 10 32. The compound of formula **4** according to claim 31, wherein:

R¹ is a group selected from the group consisting of methyl, ethyl, *n*-propyl, and isopropyl, each optionally substituted by hydroxy or fluorine;

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF₃, or NO₂.

- 15 33. The compound of formula **4** according to claim 31, wherein:

R¹ is methyl or ethyl; and

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.


- 20 34. The compound of formula **4** according to claim 33, wherein:

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, fluorine, chlorine, or bromine.

35. The compound of formula **4** according to claim 31, wherein:

- 25 R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen or fluorine.

36. A compound of formula **3**



wherein:

R is C₁-C₄-alkyl; and

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, C₁-C₄-alkyl, C₁-C₄-alkyloxy,

5 hydroxy, CF₃, CN, NO₂, or halogen,

with the proviso that at least one of the groups R³, R⁴, R⁵, R⁶, R⁷, and R⁸ is not hydrogen.

37. The compound of formula **3** according to claim 36, wherein:

10 R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF₃, or NO₂.

38. The compound of formula **3** according to claim 36, wherein:

15 R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, methyl, methyloxy, fluorine, chlorine, or bromine.

39. The compound of formula **3** according to claim 36, wherein:

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen, fluorine, chlorine, or bromine.

20 40. The compound of formula **3** according to claim 36, wherein:

R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each independently hydrogen or fluorine.